Cambridge, UK – Qkine, Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, today announced the launch of its Cell Therapy Grade proteins, engineered to support the stringent requirements of cell therapy research, process development, and GMP manufacturing.

Cell therapy is rapidly transforming modern medicine, offering new hope for patients with cancer, autoimmune conditions, and genetic disorders. However, the development and manufacturing of these therapies demand reagents of uncompromising quality, consistency, and safety. Qkine’s new Cell Therapy Grade proteins address this critical need by delivering:

• Defined manufacturing standards – Produced under controlled conditions with full traceability and regulatory support documentation
• Enhanced quality attributes – High purity, animal origin-free, low endotoxin levels, and reduced host cell protein/DNA contamination
• Scalability for clinical workflows – Consistent performance from research-grade to therapy-grade materials, enabling seamless transition to GMP production
• Regulatory readiness – Comprehensive Certificates of Analysis (CoA), Safety Data Sheets (SDS), and technical dossiers to support IND and clinical submissions

"As the cell and gene therapy field matures, the importance of starting materials that are designed for regulatory expectations cannot be overstated," said Rob Nixon, Commercial Director at Qkine. "Our Cell Therapy Grade Proteins provide developers with high-performance reagents backed by the documentation and quality systems required to advance from discovery through clinical and commercial manufacturing."

The portfolio supports a wide range of applications, including CAR-T and TCR therapies, NK cell expansion, iPSC differentiation, and ex vivo gene editing workflows.

The launch represents Qkine’s commitment to empowering the cell therapy ecosystem with high-quality, regulatory-ready tools that streamline process development, accelerate timelines, and reduce risk in bringing life-changing therapies to patients.

The Cell Therapy Grade Proteins are available globally, with customization options for scale, formulation, and regulatory documentation packages.

About Qkine

Qkine manufactures high-purity, animal origin-free growth factors, cytokines, and other complex proteins for life science life science and cell therapy applications. Based in Cambridge, UK, Qkine combines proprietary production processes with protein engineering technology to address fundamental biological, quality, and scale-up challenges to provide more reliable tools for translational research and cell and gene therapy manufacturing. 

Qkine is an ISO 9001:2015 certified company and provides full traceability and extensive product documentation. Our exceptional transparency, Qkine Nine Point Quality Commitment and scientific support are designed to support scale-up and commercial cell manufacturing. We offer flexible supply solutions including lot reservation, bulk and custom production and bespoke quality assurance assays. 

Please visit qkine.com, email [email protected] or follow us on LinkedIn.